Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: RAPT Therapeutics, Inc.

Market Cap 1.79B 1.55B 1.42B 1.34B 2.51B 170B 2.54B 16.78B 6.54B 83.08B 6.73B 6.59B 288B P/E Ratio 2025 *
-
P/E Ratio 2026 * -
Enterprise Value 1.79B 1.55B 1.42B 1.34B 2.51B 170B 2.54B 16.78B 6.54B 83.08B 6.73B 6.59B 288B EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
96.87%
Yield 2025 *
-
Yield 2026 * -
1 day+0.07%
6 months+74.68%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 6.88
Extreme 6.88
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 02/03/2026
Treasurer - 02/03/2026
Director TitleAgeSince
Director/Board Member - 02/03/2026
Director/Board Member - 02/03/2026
Date Insider Type Main position Quantity % Market Cap.
03-02Tender

Chief Technology Officer

164,742 0.5945%
03-02Tender

Director

59,858 0.2160%
03-02Tender

Chief Financial Officer

205,703 0.7423%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+597.36%-66.44% 1.79B
-0.71%-0.97%+50.38%+109.48% 54.92B
-1.22%+2.25%+43.78%+38.45% 44.31B
-1.43%+4.68%-16.02%-20.80% 22.96B
-1.99%+1.43%-3.25%+377.36% 21.12B
-2.91%-1.18%+7.21%-36.53% 16.31B
-2.38%-3.41%+5.06%-40.72% 15.19B
-1.70%+0.70%+25.27%+172.77% 13.32B
+1.48%+11.36%+22.59% - 12.48B
+4.10%+7.02%+104.41%+226.33% 11.21B
Average -0.67%+2.42%+83.68%+84.43% 21.36B
Weighted average by Cap. -0.98%+1.99%+34.29%+93.05%

Financials

2025 *2026 *
Net sales - -
Net income - -
Net Debt - -
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!